Fig. 7.

Brain microgliosis is reduced upon treatment with SSO. GFAP and Iba-1 immunoreactivities were quantified at 3 days post-injury. Quantification of Iba-1 immunoreactivity (a) and representative images of Iba-1 staining in the peri-ischemic area of the ipsilateral (b) and contralateral hemisphere (c) of vehicle-treated mouse. The lower panels (d, e) represent the corresponding areas in SSO-treated mouse. Quantification of GFAP immunoreactivity (f) and the representative images from the peri-ischemic area of the ipsilateral (g) and contralateral (h) hemisphere in vehicle-treated mouse. Panels i and j represent corresponding areas in the SSO-treated mouse. High magnification insets show GFAP and Iba-1 positive cell morphologies. Data are expressed as mean ± SEM. GFAP immunoreactivity was quantified from vehicle-treated (n = 10) and SSO-treated (n = 9) mice. Iba- 1 immunoreactivity was quantified from vehicle-treated (n = 10) and SSO-treated (n = 10) mice. *p < 0.05 and ***p < 0.001. IL ipsilateral, CL contralateral